Mainz Biomed N.V., a diagnostics company focused on early cancer detection, has announced a new collaboration with CARE diagnostica Laborreagenzien GmbH. This agreement will enhance colorectal cancer screening services by integrating Mainz Biomed's ColoAlert® test into CARE's existing online-based screening concepts, which are already used by over 15 statutory health insurance companies in Germany. The ColoAlert® test employs molecular genetic analysis of biomarkers in stool to improve detection rates, particularly in early stages. This cooperation aims to expand the distribution of ColoAlert® in the German market, aligning with the increasing demand for personalized early intervention screening solutions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。